EA201891848A1 - Фармацевтическая композиция для применения в лечении фиброза - Google Patents

Фармацевтическая композиция для применения в лечении фиброза

Info

Publication number
EA201891848A1
EA201891848A1 EA201891848A EA201891848A EA201891848A1 EA 201891848 A1 EA201891848 A1 EA 201891848A1 EA 201891848 A EA201891848 A EA 201891848A EA 201891848 A EA201891848 A EA 201891848A EA 201891848 A1 EA201891848 A1 EA 201891848A1
Authority
EA
Eurasian Patent Office
Prior art keywords
fibrosis
treatment
pharmaceutical composition
active ingredient
relates
Prior art date
Application number
EA201891848A
Other languages
English (en)
Inventor
Фуминори Сакураи
Хироюки Мидзугути
Original Assignee
Осака Юниверсити
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Осака Юниверсити filed Critical Осака Юниверсити
Publication of EA201891848A1 publication Critical patent/EA201891848A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/765—Reovirus; Rotavirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof

Abstract

Изобретение относится к фармацевтической композиции для применения в лечении фиброза, содержащего реовирус в качестве активного ингредиента.
EA201891848A 2016-02-16 2017-02-15 Фармацевтическая композиция для применения в лечении фиброза EA201891848A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2016027202 2016-02-16
PCT/JP2017/005443 WO2017141942A1 (ja) 2016-02-16 2017-02-15 線維化を治療するための医薬組成物

Publications (1)

Publication Number Publication Date
EA201891848A1 true EA201891848A1 (ru) 2019-02-28

Family

ID=59625890

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201891848A EA201891848A1 (ru) 2016-02-16 2017-02-15 Фармацевтическая композиция для применения в лечении фиброза

Country Status (10)

Country Link
US (1) US11077157B2 (ru)
EP (1) EP3417866B1 (ru)
JP (1) JP6875745B2 (ru)
KR (1) KR20180129779A (ru)
CN (1) CN109152804A (ru)
AU (1) AU2017221592A1 (ru)
CA (1) CA3018307A1 (ru)
EA (1) EA201891848A1 (ru)
PH (1) PH12018501991A1 (ru)
WO (1) WO2017141942A1 (ru)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20210098202A (ko) * 2020-01-31 2021-08-10 바이로큐어 주식회사 레오바이러스를 유효성분으로 포함하는 대장염의 예방 또는 치료용 조성물

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5525342A (en) 1994-05-20 1996-06-11 Akzo Nobel, N.V. Reovirus strain 2177 and vaccine containing same
US6136307A (en) * 1997-08-13 2000-10-24 Oncolytics Biotech Inc. Reovirus for the treatment of cellular proliferative disorders
DE10122233A1 (de) 2000-07-11 2002-01-24 Bayer Ag Verwendung von Stämmen des Parapoxvirus ovis gegen Organfibrosen
GB2383752B (en) 2000-07-11 2004-11-24 Bayer Ag Use of strains of the parapox ovis virus against organ fibrosis
ES2239928T3 (es) 2002-05-09 2009-02-16 Oncolytics Biotech Inc. Metodo para reducir el dolor utilizando virus oncoliticos.
WO2008044627A1 (fr) 2006-10-06 2008-04-17 Bachtech, Inc. Agent prophylactique/thérapeutique destiné aux troubles hépatiques utilisant un baculovirus
KR101647843B1 (ko) 2007-03-12 2016-08-11 온콜리틱스 바이오테크 인코포레이티드 변형된 서열을 갖는 레오바이러스
US10369171B2 (en) 2007-03-13 2019-08-06 Virocure, Inc. Attenuated reoviruses for selection of cell populations
TW200909581A (en) 2007-05-21 2009-03-01 Oncolytics Biotech Inc Mutant reoviruses and methods of making and using
EP2296679A4 (en) 2008-05-27 2012-03-21 Oncolytics Biotech Inc SUPPRESSION OF PRODUCTION OF PRO-INFLAMMATORY CYTOKINES DURING ONCOLYTIC REOVIRUS THERAPY
WO2012045473A1 (en) 2010-10-07 2012-04-12 Technische Universität München Viruses for the treatment of fibrosis
US9309203B2 (en) 2011-10-07 2016-04-12 Pisces Therapeutics, Llc Malignant and non-malignant disease treatment with Ras antagonists
US9738614B2 (en) 2011-10-07 2017-08-22 Pisces Therapeutics, Llc Malignant and non-malignant disease treatment with Ras antagonists

Also Published As

Publication number Publication date
CN109152804A (zh) 2019-01-04
AU2017221592A1 (en) 2018-10-04
WO2017141942A1 (ja) 2017-08-24
JPWO2017141942A1 (ja) 2018-12-20
EP3417866A1 (en) 2018-12-26
EP3417866B1 (en) 2020-12-23
CA3018307A1 (en) 2017-08-24
US11077157B2 (en) 2021-08-03
JP6875745B2 (ja) 2021-05-26
PH12018501991A1 (en) 2019-06-17
US20190151384A1 (en) 2019-05-23
EP3417866A4 (en) 2019-10-16
KR20180129779A (ko) 2018-12-05

Similar Documents

Publication Publication Date Title
MY196909A (en) Boronic acid derivatives and therapeutic uses thereof
EA201692301A1 (ru) Производные бороновой кислоты и их терапевтическое применение
EA201890201A1 (ru) Антибактериальные соединения
MX2016015093A (es) Derivados de acido boronico y sus usos terapeuticos.
MX2016016593A (es) Nuevos derivados de aminoalquibenzotiazepina y usos de los mismos.
CL2016002072A1 (es) 2-amino-3,5,5-trifluoro-3,4,5,6-tetrahidropiridinas como inhibidores de bace1 para el tratamiento de la enfermedad de alzheimer
PH12019501097A1 (en) Magl inhibitors
MX2017011997A (es) Carbamatos de piperacina y metodos de preparacion y uso.
MY187540A (en) Compounds active towards bromodomains
PH12019501102A1 (en) Magl inhibitors
EA201790273A1 (ru) Флагеллиновые композиции и их применение
MX2016012574A (es) Compuestos heteroarilo sustituidos y metodos de uso.
CL2015002897A1 (es) Inhibidores de bace1
CL2016001918A1 (es) Heteroaril amidas como inhibidores de agregación de proteína
EA201791454A1 (ru) Лекарственные формы для трансдермального введения
EA201991447A1 (ru) Снижение вязкости фармацевтических составов
BR112017000730B8 (pt) Derivados de pirrolidinona como inibidores de metap-2, e medicamentos
MX2017012596A (es) Una composicion farmaceutica y el uso de la misma.
CY1122473T1 (el) Βελτιστοποιημενο μεσαλαζiνουχο δισκιο υψηλης δοσης
MX2018005987A (es) Compuestos heterociclicos para el tratamiento de enfermedades.
EA201591717A1 (ru) Твердые формы гидрохлорида вемурафениба
DOP2018000049A (es) Compuestos para uso en aplicaciones antibacterianas
EA201691741A1 (ru) Фармацевтическая композиция
CO2018011420A2 (es) Formulaciones líquidas de fosfaplatino
EA201990162A1 (ru) Фармацевтические композиции